FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENTYVIO (vedolizumab) from Takeda Pharmaceuticals America, Inc., approving a modification to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Entyvio (vedolizumab)

Snippet

SUPPL AP for ENTYVIO (VEDOLIZUMAB)